Rob Caldwell

Rob is a toxicologist at AbbVie, where he has worked for the last 10 years. Rob’s main responsibility is to manage the preclinical toxicology strategy for drug development teams, supporting the overall safety assessment of new drugs. He works primarily on rheumatologic therapies but has also worked with antivirals and pain therapies. Prior to joining AbbVie, Rob worked at Covance Laboratories (a contract research laboratory) for 8 years where he lead the immunotoxicology program and conducted general toxicology studies for the pharmaceutical industry. Rob obtained his PhD in Immunology from Northwestern University in Chicago; where he studied mechanisms of Epstein-Barr virus latency and reactivation using transgenic mice.